Inhibrx Biosciences, Inc. Common Stock (INBX)

Price$82.39

Favorite Metrics

Price vs S&P 500 (26W)163.02%

Price vs S&P 500 (4W)35.34%

Market Capitalization$1.29B

P/E Ratio (Annual)0.55x

All Metrics

Book Value / Share (Quarterly)$0.55

P/TBV (Annual)16.73x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-15.96%

Cash Flow / Share (Quarterly)$-6.58

Price vs S&P 500 (YTD)7.55%

Net Profit Margin (TTM)-5465.64%

EPS (TTM)$-6.24

10-Day Avg Trading Volume0.27M

EPS Excl Extra (TTM)$-6.24

Revenue Growth (5Y)-36.80%

EPS (Annual)$-9.04

ROI (Annual)-129.02%

Net Profit Margin (5Y Avg)162368.22%

Cash / Share (Quarterly)$8.52

P/E Normalized (Annual)0.55x

ROA (Last FY)-95.62%

Revenue Growth TTM (YoY)550.00%

EBITD / Share (TTM)$-5.81

ROE (5Y Avg)-289.95%

Operating Margin (TTM)-5522.64%

Cash Flow / Share (Annual)$-8.91

P/B Ratio161.24x

P/B Ratio (Quarterly)143.75x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)903.66x

Net Interest Coverage (TTM)-29.14x

ROA (TTM)-54.14%

EV / EBITDA (TTM)0.75x

EPS Incl Extra (Annual)$-9.04

Current Ratio (Annual)3.93x

Quick Ratio (Quarterly)3.68x

3-Month Avg Trading Volume0.22M

52-Week Price Return669.22%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.74

P/S Ratio (Annual)991.37x

Asset Turnover (Annual)0.01x

52-Week High$94.56

Operating Margin (5Y Avg)163100.94%

EPS Excl Extra (Annual)$-9.04

CapEx CAGR (5Y)-53.06%

26-Week Price Return171.77%

Quick Ratio (Annual)3.68x

13-Week Price Return16.20%

Total Debt / Equity (Annual)12.58x

Current Ratio (Quarterly)3.93x

Enterprise Value$1,265.118

Revenue / Share Growth (5Y)-24.49%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-22.80%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-10773.31%

Cash / Share (Annual)$8.52

3-Month Return Std Dev72.58%

Net Income / Employee (TTM)$-1

ROE (Last FY)-1752.22%

Net Interest Coverage (Annual)-21.57x

EPS Basic Excl Extra (Annual)$-9.04

Receivables Turnover (TTM)4.96x

Total Debt / Equity (Quarterly)12.58x

EPS Incl Extra (TTM)$-6.24

Receivables Turnover (Annual)0.33x

ROI (TTM)-70.25%

P/S Ratio (TTM)920.56x

Pretax Margin (5Y Avg)162386.73%

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$1.33

Price vs S&P 500 (52W)634.13%

Year-to-Date Return11.68%

5-Day Price Return13.90%

EPS Normalized (Annual)$-9.04

ROA (5Y Avg)131.06%

Net Profit Margin (Annual)-10773.46%

Month-to-Date Return31.24%

Cash Flow / Share (TTM)$-4.22

EBITD / Share (Annual)$-8.58

Operating Margin (Annual)-10386.54%

LT Debt / Equity (Annual)12.58x

ROI (5Y Avg)183.12%

LT Debt / Equity (Quarterly)12.58x

EPS Basic Excl Extra (TTM)$-6.24

P/TBV (Quarterly)7.50x

P/B Ratio (Annual)143.75x

Pretax Margin (TTM)-5465.50%

Book Value / Share (Annual)$0.55

Price vs S&P 500 (13W)13.33%

Beta2.57x

Revenue / Share (TTM)$0.08

ROE (TTM)-255.98%

52-Week Low$10.84

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

2.17

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
INBXInhibrx Biosciences, Inc. Common Stock	920.56x	550.00%	—	—	$82.39
AMGNAmgen Inc	5.20x	9.95%	73.30%	2.93%	$350.16
GILDGilead Sciences Inc	5.71x	2.40%	78.83%	133.64%	$135.87
ARGXargenx SE American Depositary Shares	12.59x	89.56%	150.91%	—	$834.45
BNTXBioNTech SE American Depositary Share	9.06x	-11.81%	84.21%	—	$105.19
BIIBBiogen Inc. Common Stock	2.72x	2.22%	75.69%	-18.77%	$183.34
MRNAModerna, Inc. Common Stock	10.91x	-39.93%	70.32%	—	$54.59
NBIXNeurocrine Biosciences Inc	4.64x	21.45%	98.18%	2.31%	$131.59
EXELExelixis Inc	4.89x	6.85%	96.39%	31.10%	$43.61
TECHBio-Techne Corp.	7.72x	1.64%	66.60%	-20.58%	$60.58
IBRXImmunityBio, Inc. Common Stock	74.42x	668.31%	99.34%	—	$8.20

About

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapies using its proprietary protein engineering platform. The company's pipeline includes INBRX-109 and INBRX-106, multivalent therapeutic candidates designed to optimize target engagement and agonist activity.